Clinical Trial Update: Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of multi-epitope TARP peptide autologous dendritic cell vaccination in men with stage D0 prostate cancer (terminated; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Multi-epitope TARP peptide autologous dendritic cell vaccination (TARP peptide autologous dendritic cell vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasms, Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-03-08